Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from aminoglycoside-treated vaginal tissues.

ABSTRACT: C57 Bl/6 mice were treated subcutaneously with Depo-provera. Five days after Depo treatment mice were treated intravaginally with 1mg neomcyin or equivalent volume of saline every day for six days. On the seventh day, mice were scarificed, vaginal tissue harvested and RNA extracted. Matrix normalized data is provided as neomycin expression data normalized against pbs expression data.

ORGANISM(S): Mus musculus

PROVIDER: GSE94909 | GEO | 2017/02/16

SECONDARY ACCESSION(S): PRJNA374792

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from murine vaginal samples following adjuvant treatment

Project description:Vaccine research today is focused on using safer, highly purified or recombinant antigens with poor immunogenicity, which has created a need for potent adjuvants. Rational design of effective and safe mucosal adjuvants for human use necessitates a thorough understanding of the mode of action of successful candidate adjuvants. We used microarray to comprehend the molecular signatures of mucosal adjuvants in the mouse vagina. The adjuvants studied, CpG-ODN and ‚âà√≠¬¨¬±-GalCer have previously been shown to be potent mucosal adjuvants in mice when administrered together with a glycoprotein from HSV-2. Two individual experiments were performed, called ES1 and ES2, each experiment contained 4 groups of mice. All mice were pre-treated with progesteron (DP) before intravaginally recieveing either CpG ODN, alpha-GalCer or their respective buffers, PBS and PBS/Tween. Vaginas were excised at 3 different time-points; 4h, 24h and 48h following adjuvant delivery.

2011-12-30 | E-GEOD-27149 | biostudies-arrayexpress

scRNAseq of mock, HSV-1 or HSV-2 infected C57BL/6 Vaginal tissue at 5 days post infection

Project description:Purpose: To compare single cell transcriptional profiling (scRNAseq) of different murine genital herpes infection models with HSV1-McKrae and HSV2-186. Method: DMPA-treated WT C57BL/6 mice were infected with HSV1-McKrae, HSV2-186 or PBS intravaginally. Vaginal tissues were harvested at 5 days post infection, live cells were sorted, a minimum of 16,000 cells were used for scRNAseq. Results: By tSNE visualization of 21,633 cells across all samples, 17 distinct clusters were resolved. We found significantly increased levels of Interferons-Stimulated-Genes (ISGs) in the neutrophils potentially contributing to disease onset and progression in HSV2 genital infections. Conclusion: Our study is the first comparison between the transcriptional signature of two genital herpes model- namely HSV1 and HSV2. Generated by scRNAseq, this study would provide researchers with gene candidates associated with the disease progression and inflammation induced by genital infections with HSV1 and HSV2.

2020-12-31 | GSE161336 | GEO

Colon mucosa of F344 rats: control treated with 5% DSS vs Resveratrol + 5% DSS

2009-01-28 | GSE14544 | GEO

Multiplexed quantitative proteomics in an autoimmune mice model of myocarditis (EAM)

Project description:We performed a high-throughput, multiplexed quantitative proteomics analysis to determine protein abundance changes produced by BML-111 treatment in EAM and Ctrl mice. EAM was induced in 7 weeks-old BALB/c female mice by immunization at days 0 and 7 with a subcutaneous injection of 350 μg of murine cardiac myosin (MyHCα) in a 1:1 emulsion with complete Freund’s Adjuvant (SIGMA). MyHCα was isolated from hearts of Balb/c mice; control mice were injected with a 1:1 emulsion of physiological saline solution with complete Freund’s Adjuvant. Mice were treated daily for two weeks from day 7 by intraperitoneal injection with two complementary treatments: 1mg/Kg BML-111(Enzo Life Science) or its vehicle (2.5% ethanol). The proteomics analysis was performed in heart tissue protein extracts (four animals per group: Ctrl+Veh, EAM+Veh, Ctrl+BML and EAM+BML.

2022-12-07 | PXD024345 | Pride

Colon mucosa of F344 rats: control treated with 5% DSS vs Resveratrol + 5% DSS

Project description:Expression profile of colon mucosa of F344 rats treated with 5% DSS during five days vs colon mucosa of F344 rats pre-treated for 20 days with resveratrol 1mg/kg/day and during the five days of 5% DSS administration Keywords: Inflammation experiment Two conditions experiment, colon mucosa of F344 rats treated 5% DSS for 5d vs colon mucosa of F344 rats pretreated with 1mg/kg/day resv + 5% DSS for 5d. 8 Biological samples for each group

2009-01-27 | E-GEOD-14544 | biostudies-arrayexpress

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes were isolated from PBMCs of vaccinated subjects (2 antibiotic treated, 3 controls) at day 0 and 30 using FACS. RNA-seq was used to analyze the transcriptional landscape in these cells.

2021-06-25 | GSE166063 | GEO

Aortic Effects of Thyroid Hormone in Male Mice

Project description:Test for thyroid hormone regulation of genes expressed in the abdominal aorta of C57Bl6 mice. Comparison between mice treated with 1mg/L Thyroxin in drinking water for 4 days compared to controls.

2018-08-28 | GSE119065 | GEO

Single-cell analysis of the epigenomic and transcriptional landscape of innate immunity to seasonal and adjuvanted pandemic influenza vaccination in humans [ATAC-seq]

Project description:Human subjects were vaccinated with seasonal influenza vaccine at day 0 (TIV, 2014-2015). A subgroup of subjects (abx) received an additional oral antibiotic regimen, consisting of neomycin, vancomycin, and metronidazole, between days -3 and 1. CD14+ monocytes, mDCs, and pDCs were isolated from PBMCs of vaccinated subjects (3 antibiotic treated, 5 controls) at day -21 (BL), 0 and 30 using FACS. ATAC-seq was used to analyze the chromatin accessibility landscape in these cells.

2021-06-25 | GSE166180 | GEO

Evaluation of Rheum ribes L. aqueous extract effect on neuropathy

Project description:Intervention 1: Intervention group: Patients randomly enter the intervention group, and use 5 ml of the prescribed extract for 7 days from the second day of chemotherapy until the seventh course of chemotherapy. Intervention 2: Control group: Patients randomly enter the control group, and use 5 ml of the placebo for 7 days from the second day of chemotherapy until the seventh course of chemotherapy. Primary outcome(s): . Peripheral neuropathy. Timepoint: End of day 7 after each chemotherapy course until the seventh term of chemotherapy. Method of measurement: questionnaire. Study Design: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Double blind, Blinding description: Double blind.

| 2484005 | ecrin-mdr-crc

RNA-Seq from the colon tissues of DSS treated mice receiving either EP4-D, a selective E-type prostanoid receptor 4 agonist or vehicle

Project description:The experiment was designed to identify transcriptomic changes induced by selective EP4 agonism during experimental colitis. The mice received 1mg/ kg of the selective EP4 agonist, EP4-D or sterile phosphate buffered saline as vehicle control orally once per day concomitant with 3% DSS in drinking water. The DSS treatment was stopped on day 5 and mice were provided access to autoclaved drinking water for 3 additional days along with agonist and vehicle treatments once daily as described above. At the end of the treatment period, colon tissues from the mice were harvested, RNA isolated, and sequenced to identify transcriptional changes.

2021-02-01 | E-MTAB-9820 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data